Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Estrogen receptor α-mediated signaling inhibits type I interferon response to promote breast cancer

ABSTRACT: Estrogen receptor α-mediated signaling inhibits type I interferon response to promote breast cancer

PROVIDER: PRJNA838372 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR19215701_1.fastq.gz	Fastqsanger.gz
	SRR19215701_2.fastq.gz	Fastqsanger.gz
	SRR19215702_1.fastq.gz	Fastqsanger.gz
	SRR19215702_2.fastq.gz	Fastqsanger.gz
	SRR19215703_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Estrogen receptor α-mediated signaling inhibits type I interferon response to promote breast cancer

Project description:To investigate the molecular mechanisms by which estrogen receptor α (ERα) inhibits type I IFN-induced signaling. We identified genes induced by ERα signaling using data obtained from RNA-seq of MCF7 cells treated or untreated with selective ERα agonist propyl pyrazole triol (PPT).

2022-05-18 | GSE203058 | GEO

α-ketogluatrate inhibits osteoclastogenesis

Project description:α-ketogluatrate inhibits osteoclastogenesis

| PRJNA650523 | ENA

Estrogen Promotes Mandibular Condylar Fibrocartilage Chondrogenesis and Inhibits Degeneration Via Estrogen Receptor Alpha in Female Mice

Project description:Estrogen Promotes Mandibular Condylar Fibrocartilage Chondrogenesis and Inhibits Degeneration Via Estrogen Receptor Alpha in Female Mice

| PRJNA433406 | ENA

Nuclear Estrogen Receptor alpha (ERα) interactome following estrogen and antiestrogen treatment.

Project description:The Estrogen Receptor alpha (ERα) controls key cellular functions in hormone responsive breast cancer by assembling in large functional multiprotein complexes. ERα ligands are classified as agonists and antagonist, according to the response they elicit, thus the molecular characterization of the of ERα nuclear iteractome composition following estrogen and antiestrogen stimulation whose is needed to understand their effects on estrogen target tissues, in particular breast cancer. To this aim interaction proteomics coupled to mass spectrometry (MS) was applied to map the ERα nuclear interacting partners in MCF7 breast cancer cell nuclei following estrogen and antiestrogen stimuli.

2020-09-02 | PXD018709 | Pride

Cooperative interaction between retinoic acid receptor-alpha and estrogen receptor in breast cancer.

Project description:Retinoic acid receptor-alpha (RAR alpha) is a known estrogen target gene in breast cancer cells. The consequence of RAR alpha induction by estrogen was previously unknown. We now show that RAR alpha is required for efficient estrogen receptor-alpha (ER)-mediated transcription and cell proliferation. RAR alpha can interact with ER-binding sites, but this occurs in an ER-dependent manner, providing a novel role for RAR alpha that is independent of its classic role. We show, on a genome-wide scale, that RAR alpha and ER can co-occupy regulatory regions together within the chromatin. This transcriptionally active co-occupancy and dependency occurs when exposed to the predominant breast cancer hormone, estrogen--an interaction that is promoted by the estrogen-ER induction of RAR alpha. These findings implicate RAR alpha as an essential component of the ER complex, potentially by maintaining ER-cofactor interactions, and suggest that different nuclear receptors can cooperate for effective transcriptional activity in breast cancer cells. RAR alpha silenced breast cancer MCF-7 cell lines or control siRNA in the presence of estrogen or a vehicle. MCF-7 cells were hormone-depleted for 3 d and treated with 100 nM estrogen for 12 h. There were three biological replicates for each of the four different groups.

2010-06-16 | E-GEOD-22213 | biostudies-arrayexpress

Estrogen-independent molecular actions of mutant estrogen receptor alpha in endometrial cancer

Project description:Estrogen-independent molecular actions of mutant estrogen receptor alpha in endometrial cancer

| PRJNA548072 | ENA

Expression data of interferon-alpha treated Huh-7 cells

Project description:Hepatitis C virus (HCV) infection is primarily treated with a pegylated interferon alpha based therapy, a regime that induces antiviral effects through the upregulation of many interferon-stimulated genes (ISGs). Whilst a number of anti-HCV ISGs have previously been identified, others may also be involved. Micorarrays were used to validate the presence of ISGs within subtracted libraries generated using the related techniques of suppression subtractive hybridisation and mirror orientation selection, which had initally been impllemented to isolate clones of ISGs following the interferon-alpha treatment of Huh-7 cells. Microarray data was generated for both untreated and interferon-alpha treated Huh-7 cells. No replicates were performed, however the microarray data was verified via the use of non-parametric (spearman) correlation analysis with RT-PCR data that had been generated using the same Huh-7 cell total RNA samples as the microarray experiments earlier.

2011-11-30 | E-GEOD-34022 | biostudies-arrayexpress

Mass spectrometry analysis of estrogen receptor α -interacting proteins.

Project description:Quantitative mass spectrometry analysis using tandem mass tags (TMT) labelling of estrogen receptor α (ERα) pull downs. Co-immunoprecipitated proteins using a anti Erα antibody were compared quantitatively with material recovered in a mock to identify ERα-interacting proteins.

2022-10-14 | PXD025018 | Pride

Estrogen receptor alpha targeting in liver cancer and breast cancer

Project description:This study is to identify estrogen receptor alpha targeting in liver cancer and breast cancer using RNA-Seq and ChIP-Seq and reveal the mechanisms underlying estrogen receptor alpha in the regulation of liver cancer and breast cancer.

2023-04-06 | GSE215384 | GEO

EndoC-betaH1 cells treated with interferon alpha

Project description:EndoC-betaH1 cells were treated with 2000 U/mL interferon alpha for 8 or 24h and submitted to proteomic analysis.

2020-04-15 | PXD014244 | Pride